Fig. 4
From: Managing adherence, exposure, and toxicity in oral anticancer therapies
Kaplan–Meier analysis of OS by occurrence of HFSR grade 2 (Yes or No) at any time in regorafenib-treated patients. CI, confidence interval; HFSR, hand-foot skin reaction; HR, hazard ratio; OS, overall survival